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Background: The commercial NMP-22 urine assays for bladder cancer (BCa) detect nuclear mitotic apparatus
protein 1 (NUMA1) using monoclonal antibodies. It remains unclear whether these assays are monitoring a tumor
antigen or some other phenomenon associated with the disease state. In this study, we investigated the influence
of urinary cellular and protein concentration, and hematuria on the performance of the NMP-22 tests in an
experimental model.
Methods: Pooled urine from healthy subjects were spiked with varying concentrations of benign (UROtsa) cells,
cancer cells (RT4, T24, KU-7 and UM-UC-14), whole blood or serum, prior to analysis with both NMP22W Bladder
Cancer ELISA test and the NMP22W BladderChekW point-of-care test.
Results: Urines from control subjects were negative for NMP-22. The addition of whole blood at 50ul/10 ml, but
not serum, resulted in a false-positive result. Furthermore, the addition of a high concentration of benign urothelial
cells (106) or the cell lysate from these cells (306 μg protein) resulted in a false-positive result. High concentrations
of pooled-cancer cells (106) or cell lysate (30.6 μg and above) resulted in a positive NMP-22 assay. Concordance
between the NMP-22 ELISA assay and the NMP-22 point of care assay was >90%.
Conclusions: Rather than detecting a specific tumor antigen, urinary NMP-22 assays may be measuring the
cellularity or amount of cell turnover that may be introduced into the urine by a variety of conditions, including
surface shedding from bladder tumors. The absence of significant urinary cellularity in some cases due to lesion
characteristics or the timing of sampling may result in false-negative NMP-2 assays.
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Non-invasive urine tests for the early detection or post-
surgical surveillance of bladder cancer (BCa) are highly
desirable for both patient and healthcare system. Cur-
rently, voided urinary cytology (VUC) is the most widely
used non-invasive urine test, with reported sensitivities
ranging from 13–75% and specificities ranging from 85–
100% [1,2]. A couple of single-biomarker urinalysis
assays have been developed for use in this context. One
is the bladder tumor antigen (BTA) test, which detects
urinary complement factor H-related proteins using
monoclonal antibodies [3]. Two assay formats, BTA
stat™ and BTA TRAK™ (Polymedco Inc. Cortlandt
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reproduction in any medium, provided the orand surveillance of BCa in urine samples. For BCa detec-
tion, urinary BTA tests have diagnostic sensitivities ran-
ging from 29–83% and specificities ranging from 56–86%
[4,5]. Recently, Oge et al. demonstrated that hematuria
adversely affects the accuracy of BTA assays [6].
Another commercial assay that has been used for BCa
detection in voided urine samples is the nuclear matrix
protein-22 (NMP-22) test, which detects the nuclear mi-
totic apparatus protein 1 (NUMA1), using monoclonal
antibodies [7]. Two assay formats, the NMP22W Bladder
Cancer ELISA Test Kit and the NMP22W BladderChekW
point-of-care test (Alere Scarborough, Inc. Waltham,
MA), are FDA approved for the detection and surveil-
lance of BCa in urine samples. For BCa detection, urin-
ary NMP-22 tests have diagnostic sensitivities ranging
from 47–100% and specificities ranging from 55–98%
[8,9]. It remains unclear whether the NMP-22 test is
monitoring the increased expression of a bona fideLtd. This is an Open Access article distributed under the terms of the Creative
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with BCa such as hematuria or urothelial turnover. Not-
ing the limitations of the BTA assays, we investigated
the influence of urinary cellular concentration, urinary
protein concentration and hematuria on the perform-
ance of the NMP-22 tests in an experimental model.
Methods
Clinical sampling and processing
Under IRB approval and informed consent, serum sam-
ples were collected from 20 men with no previous his-
tory of BCa and 20 men with newly diagnosed BCa.
Serum was isolated, snap frozen and stored at -800C
until use. Two hundred ml of urine and 10 ml of whole
blood were collected from three healthy subjects. None
of the subjects had any current or history of urological
disorder. Microscopic examination of the urine samples
showed no cells and all samples were tested by urinary
dipstick test for abnormalities. Pertinent clinical infor-
mation for each subject was recorded.
Cell lines and culture
Human bladder cancer cell lines; RT4 (ATCC, Manassas,
VA), T24 (ATCC, Manassas, VA), UM-UC-14 (a gener-
ous gift from Dr. H. Bart Grossman, The University of
Texas M.D. Anderson Cancer Center, Houston, TX),
and KU-7 (a generous gift from Dr. Motoyoshi Tanaka,
Nara University Medical School, Nara, Japan) were avail-
able for analysis. The benign human bladder cell line,
UROtsa, was a generous gift from Dr. Donald Sens at
the University Of North Dakota School Of Medicine
(Grand Forks, ND). T24, UM-UC-14 and KU-7 cell lines
were maintained in RPMI1640 media. UROtsa and RT4
cells were maintained in low-glucose DMEM and
McCoy’s 5A medium (Life Technologies, Inc., Gaithers-
burg, MD), respectively. All media were supplemented
with 10% fetal bovine serum, 100 units/ml of penicillin
and 100 μg/ml of streptomycin. All cells were incubated
at 37°C in a humidified atmosphere of 5% CO2 in air.
Experimental model
To create the experiment model, 200 ml of freshly
voided urine samples from three healthy controls were
collected in sterile containers. All subjects’ urines tested
negative for NMP-22 using both the NMP22W Blad-
derchekW test and the NMP22W ELISA kit assay. The
urine samples from the three subjects were pooled,
mixed and distributed into 10 ml aliquots in 15 ml cen-
trifuge tubes. The human bladder cell lines were washed,
trypsinized and counted. For UROtsa, 1 ×104 (low con-
centration), 1 ×105 (medium concentration) and 1 ×106
(high concentration) cells were each added to triplicate
10 ml pooled urine samples. Equal numbers of RT4,
T24, UM-UC-14 and KU-7 were pooled, and 1 ×104(low concentration), 1 × 105 (medium concentration) and
1 × 106 (high concentration) cells were added to triplicate
10 ml pooled urine aliquots. For cell lysate analyses, 1 ×
106 cells of each cell line were lysed by RIPA buffer
(Pierce, Rockford, IL) and total protein concentration
measured. The total proteins extracted from 1 × 106 cells
of UROtsa, RT4, T24, UM-UC-14 and KU-7 were 431ug,
369ug, 174ug, 261ug and 293 μg, respectively, with a
mean total protein extract of 306 μg. In the following
experiments, 3.06 μg, 30.6 μg and 306 μg of cellular pro-
teins corresponding to 1 × 104 (low concentration), 1 ×
105 (medium concentration) and 1 ×106 (high concentra-
tion) cells, were used. These UROtsa lysates and pooled
cancer cell lysates were added to pooled urine samples in
triplicate. To monitor hematuria influence, pooled whole
blood (1, 5, 20 and 50 μl) from 20 subjects with and 20
subjects without BCa was added analyzed in triplicate in
10 ml urine samples. Serum samples from 20 subjects
with and 20 subjects without BCa were pooled. Serum
protein concentrations similar to the cellular lysate con-
centrations, 3.06 μg (low concentration), 30.6 μg (medium
concentration) and 306 μg (high concentration) were
added to triplicate pooled urine samples. Figure 1 illus-
trates the experimental model.
Reagents and tests
The NMP-22 assays: NMP22WBladderChek TestW and
NMP22W Bladder Cancer ELISA Test Kit were pur-
chased from Alere Scarborough, Inc. (Waltham, MA).
The NMP22WBladderchek TestW was performed by add-
ing 4 drops of urine into the well of a disposable test de-
vice for all urine samples. Results were considered to be
positive if any band, no matter how faint, appeared in
the test zone 30 min after adding the urine to the well.
The NMP-22 ELISA assay was conducted according to
the manufacturer’s instructions. Briefly, 200 μl of urine
was added to the 96-well plate. Calibration curves were
prepared using purified standards for each protein
assessed. Curve fitting was accomplished by linear re-
gression following manufacturer’s instructions. Based on
published literature, a cutoff value of 10 U/mL was used
to define a positive NMP-22 ELISA assay [8,10]. Urinaly-
sis was performed with MULTISTIX PRO Reagent Strips
(Bayer HealthCare, Elkhart, IN) to assess protein. In
addition, urinary protein concentration was determined
using Pierce 660-nm Protein Assay Kit (Thermo Fisher
Scientific Inc., Waltham, MA, USA).
Data analysis
A Student t-test was used to compare NMP-22 expres-
sion levels in cell lines. Statistical significance in this
study was set at p < 0.05 and all reported p values were
2-sided. All analyses were performed with PRISM soft-
ware version 5.00 (GraphPad Software, San Diego, CA).
Figure 2 NMP-22 ELISA assay of human bladder cell lines. The
human bladder cancer cell lines, RT4, T24 and UM-UC-14 had
elevated NMP-22 levels compared to the benign UROtsa human cell
line. Levels of NMP-22 in the KU-7 human bladder cancer cell line
were not elevated compared to UROtsa. Significance (p< 0.05) was
assessed by Student t test. n.s., not significant.
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Figure 1 Schematic of experimental model. Low concentration
(1×104), medium concentration (1× 105) and high concentrations
(1× 106) of UROtsa benign human bladder cells, or a mixture of
human bladder cancer lines, RT4, T24, UC-UM-14 and KU-7 were
added to 10 ml of pooled urine from three healthy controls. The
cellular lysate associated with low protein concentration (3.06 μg),
medium concentration (30.6 μg) and high concentrations (306 μg)
of UROtsa benign human bladder cells or a mixture of human
bladder cancer lines, RT4, T24, UC-UM-14 and KU-7 were added to
10 ml of pooled urine from three healthy controls. In addition,
whole blood (1, 5, 20 and 50 μl) and serum (3.06, 30.6 and 306 μg
protein) were added to 10 ml of pooled urine from healthy controls.
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The NMP22W Bladder Cancer ELISA Test was per-
formed on a panel of human bladder cell lines (Figure 2).
The cancer cell lines, RT4, T24 and UM-UC-14, had sig-
nificantly higher NMP-22 levels than the benign cell
line, UROtsa (p < 0.05). One bladder cancer cell line,
KU-7, did not express higher NMP-22 levels than
UROtsa. The NMP-22 level recorded for a pool of the
four cancer cell lines was significantly higher than the
NMP-22 level of UROtsa (24,299 ± 2,110 U/mg vs.
12,641 ± 1,973 U/mg, p < 0.05).
The results from applying both the NMP22W Bladder
Cancer ELISA Test and the NMP22W BladdercheckW
Test on samples taken from our experimental model are
described in Table 1 and Figure 3. Urine samples fromIndividual subjects, and a pool of those samples were
negative for NMP-22. Whole cells or cell lysates of the
cancer cell line pool and UROtsa cells were added to the
pooled urine sample and re-analyzed using both NMP-
22 ELISA tests. Only the high concentration (1 × 106) of
UROtsa or pooled cancer cells produced a positive
NMP-22 test. Cellular lysates from 1× 105 and 1 × 106
pooled cancer cells, and from 1× 106 UROtsa cells pro-
duced a positive result. The only discordance seen be-
tween the NMP22W Bladder Cancer ELISA Test and the
NMP22W BladdercheckW test was seen when UROtsa
lysate (1 × 105 cells) produced a positive NMP22W Blad-
dercheckW test but a negative NMP-22 ELISA assay.
The addition of whole blood at 5ul and 20ul per 10 ml
of urine did not cause a positive NMP-22 result, but
spiking 50 μl/10 ml did produce false-positive NMP-22
assays. The fact that the false-positive effect was cellular
was confirmed by the addition of pooled serum samples
obtained from subjects with or without BCa. Neither
serum sample caused NMP-22 test positivity, even at the
highest level of 306 ug of protein. Overall, the concord-
ance rates between the NMP22W BladdercheckW test and
the NMP22W ELISA kit assay was > 90% throughout the
analyses.
Discussion
Using a novel experimental model, we evaluated a num-
ber of factors that may influence the NMP-22 urine
tests. Although the model does not mimic the actual
physiological situation exactly, the aim was to test
whether the NMP-22 analyte could originate from blood
(serum or whole blood) or benign cells of urothelial ori-
gin. Previous studies have investigated the influence of
blood in the NMP-22 assay. Atsu et al. reported that
when whole blood was added to a urine sample, positive
NMP-22 results increased in parallel with the increase in
Table 1 Results of NMP22W BladdercheckW Test
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the leukocyte count in the urine sediment also had a sig-
nificant impact, and the investigators concluded that py-
uria and hematuria significantly affected urinary NMP-22
[11]. In our study, the influence of blood was confirmed,
but we also showed that spiking with intact, benign or
cancerous cells caused a positive NMP-22. As expected,
cellular lysate from those cells had a greater effect.
NMP-22 (nuclear matrix protein-22) is also known as
nuclear mitotic apparatus protein (NUMA or NUMA-1)
[12,13]. The function of NUMA-1 is to provide structuralsupport for the nucleus and to ensure the correct separ-
ation of genetic material during mitosis into the respective
daughter cells through mitotic spindle stabilization [14].
To see how NUMA-1 is distributed in healthy and diseased
tissues we queried the Human protein Atlas (http://www.
proteinatlas.org). The Atlas provides immunohistochemis-
try data, and expression is confirmed in the majority of
cases using 2 or more antibodies for the same antigen [15].
NUMA-1 expression data is available on a wide range of
tissues, including both normal and diseased urinary blad-
der tissue. An overview of the staining patterns across tis-
sues confirms that NUMA-1 is expressed in all tissues with
an epithelial component, but also in glandular cells, cells of
the lymph node and macrophages. Notably, it is apparent
that the normal urothelial lining of the bladder expresses
NUMA-1 at a high level (Figure 4). As reported previously,
NUMA-1 is localized to the nucleus primarily, but there is
granular cytoplasmic staining of NUMA-1 protein also.
Carcinoma tissues typically have NUMA-1 expression
across the tumor, with some expected heterogeneity, but
intensity of staining is often less than that seen in the nor-
mal urothelia (Figure 4), and the cytoplasmic component is
less pronounced. The imunohistochemistry data suggest
that at the interface between urine and bladder lining, the
cellular expression level will be at least as strong in normal
tissue as in tumor tissue.
We also queried public databases for transcriptome
profile data. NUMA-1 expression is reported to be
increased in tumors of a variety of tissues, but given the
epithelial expression profile of NUMA-1 this can be mis-
leading unless the details of how the cellular compos-
ition of solid tissue specimens was corrected for in
specific studies are known. However, of note, the profile
databases do report that NUMA-1 mRNA is high in
whole blood. This is of interest because blood incursion
into the bladder can create difficulties in interpretation
of urine tests for bladder cancer. We showed in our ex-
perimental model that spiking of NMP-22 negative urine
with whole blood can cause a false-positive result.
If the NMP-22 test is measuring a nuclear protein that is
present in the majority of cell types throughout the body,
and one that is particularly prevalent in the normal bladder
lining, how does the test perform reasonably well for the
detection of BCa. The test could be detecting NMP-22 that
is introduced into the urine by hematuria, and since
hematuria is the most associated symptom of bladder can-
cer, then the test would perform no better than a test for
hemoglobin as long as the threshold and sensitivity of the
two assays were comparable. Conversely, measuring NMP-
22 introduced by bleeding would impact the sensitivity of
the test, calling falsely positive cases that had hematuria
through non-malignant causes such as infection or trauma.
Alternatively, perhaps the NMP-22 test is a measure of the
release and lysis of urothelial cells into the urine. Bladder
0 0 0 0 0 0 0 0 0 0 0 0 0
UROtsa Cancer UROtsa Cancer
cells cells
Non-cancer Cancer
Original urine Cell lysate Whole cell Serum
Figure 3 NMP-22 ELISA assay of the experimental model. Positive NMP assays were elicited by high concentrations of UROtsa cells, pooled
cancer cells, cell lysate from UROtsa, and medium and high concentrations of cell lysate from pooled cancer cells. Mean levels are depicted by
long horizontal lines. Error bars indicate standard deviations.
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cells into the urine relative to the normal turnover of
healthy urothelia. The total number of urothelia shed per
unit of time will be greater if the patient has a bladder le-
sion. NMP-22 is a nuclear scaffold protein and is not
known to be secreted, thus, cell lysis must occur for the
NMP-22 test to detect soluble protein. If cell lysis occurs
at a constant rate, then the increased number of cells
released into the urine in the presence of a lesion may suf-
fice for a test, but it is also possible that tumor cells lyse in
urine more readily than normal urothelia, thereby amplify-
ing the test to some extent. A likely scenario is that aA B
Figure 4 Immunostaining of NMP-22 (NUMA1) in normal urothelia an
Atlas web portal. Top panels show magnified insets of tissue microarray im
37 years. B, normal tissue from a male of 51 years. C, bladder carcinoma tis
of 78 years. The normal urothelial layer, and carcinoma tissues display stroncombination of these factors (more cells released and lysed,
and the presence of blood) contribute to the NMP-22 test
result. As long as the test outperforms VUC, one can argue
that it has value, but identifying what any bladder cancer
test is actually measuring would seem to be pertinent and
should enable improvement of a given test, or provide
insight into how best to combine multiple markers.
Other investigators have associated false-positive NMP-
22 tests with instrumentation of the genitourinary tract
and inflammation [16] and grade of urinary hematuria
[17]. Specifically, Huber et al. reported from a large pro-
spective screening study that NMP-22 outcomes areC D
d bladder cancer tissue. Images originate from the Human Protein
ages directly below. A, normal urinary bladder tissue from a male of
sue from a male of 51 years. D, bladder carcinoma tissue from a male
gly positive nuclear staining and less intense cytoplasmic staining.
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concentrated urine (creatinine > 2.5 g/L) [18]. Further-
more, impaired renal function (i.e., reduced glomerular fil-
tration rate) has been linked to false-positive NMP-22
results, while proteinuria associated with impaired renal
function is associated with reduction in urinary cytology
specificity [19]. Similar to other urine-based assays, NMP-
22 has a disappointingly low sensitivity for small, low-
grade tumors [20]. Based on our results we believe the
reduced sensitivity is related to low tumor burden and
consequent low cell turnover. Perhaps if NMP-22 urinary
protein was normalized to total urinary proteins, or to
urinary creatinine, then a NMP-22 assay may be better
able to diagnose these small, low-grade tumors, which are
the most common, yet least threatening of the tumors.
Conclusions
In combination, these findings raise the question of
whether the NMP-22 tests are detecting a bona fide
tumor antigen in urine samples or detecting a surrogate
for cellularity/cell turnover or hematuria introduced into
the urine by a friable bladder tumor. The absence of sig-
nificant urinary cellularity in subjects with BCa may re-
sult in false-negative NMP-22 assays.
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